Renoprotective effects of glp1r agonists and sglt2 inhibitors

Select a language for the TTS:
UK English Female
UK English Male
US English Female
US English Male
Australian Female
Australian Male
Language selected: (auto detect) - EN

Nature

Play all audios:

New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The

renoprotective efficacy of liraglutide is not, however, as great as that reported for the sodium-glucose cotransporter 2 inhibitor emplagiflozin in the EMPA-REG OUTCOME trial. Access through

your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature

Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access

$209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are

calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Muskiet, M. H. _ et al_.

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. _Nat. Rev. Nephrol._ 13, 605–628 (2017). Article CAS Google Scholar * DeFronzo, R. A. _ et al_. Renal,

metabolic and cardiovascular considerations of SGLT2 inhibition. _Nat. Rev. Nephrol._ 13, 11–26 (2017). Article CAS Google Scholar * Mann, J. F. _ et al_. Liraglutide and renal outcomes

in type 2 diabetes. _N. Engl. J. Med._ 377, 839–848 (2017). Article CAS Google Scholar * Wanner, C. _ et al_. Empagliflozin and progression of kidney disease in type 2 diabetes. _N. Engl.

J. Med._ 375, 323–334 (2016). Article CAS Google Scholar * Marso, S. P. _ et al_. Liraglutide and cardiovascular outcomes in type 2 diabetes. _N. Engl. J. Med._ 375, 311–322 (2016).

Article CAS Google Scholar * Zinman, B. _ et al_. Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. _Stroke_ 48, 1218–1225

(2017). Article CAS Google Scholar * Lewis, E. J. _ et al_. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

_N. Engl. J. Med._ 345, 12 (2001). Google Scholar * Brenner, B. M. _ et al_. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. _N.

Engl. J. Med._ 345, 12 (2001). Article Google Scholar * Hocher, B. Adenosine A1 receptor antagonists in clinical research and development. _Kidney Int._ 78, 438–445 (2010). Article CAS

Google Scholar * Tsuprykov, O. _ et al_. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats

with 5/6 nephrectomy. _Kidney Int._ 89, 1049–1061 (2016). Article CAS Google Scholar Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Key Laboratory of Study and

Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, Changsha, 410013, China Berthold Hocher * Institute of Nutritional Science, University

of Potsdam, 14558, Nuthetal-Potsdam, Germany Oleg Tsuprykov Authors * Berthold Hocher View author publications You can also search for this author inPubMed Google Scholar * Oleg Tsuprykov

View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Berthold Hocher. ETHICS DECLARATIONS COMPETING INTERESTS B.H. is a

consultant for Boehringer Ingelheim on the development of dipeptidyl peptidase 4 (DPP4) inhibitors and has received research funding from this company for investigation of the renal effects

of the DPP4 inhibitor linagliptin. O.T. declares no competing interests. POWERPOINT SLIDES POWERPOINT SLIDE FOR TABLE 1 RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE

CITE THIS ARTICLE Hocher, B., Tsuprykov, O. Renoprotective effects of GLP1R agonists and SGLT2 inhibitors. _Nat Rev Nephrol_ 13, 728–730 (2017). https://doi.org/10.1038/nrneph.2017.140

Download citation * Published: 09 October 2017 * Issue Date: December 2017 * DOI: https://doi.org/10.1038/nrneph.2017.140 SHARE THIS ARTICLE Anyone you share the following link with will be

able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing

initiative